Lupus & antiphospholipid syndrome
Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus
Authors' conclusion
Thus, early B cell changes could be used to predict treatment response, and their changes could be predicted from baseline T cell phenotypes, indicating the importance of B and T cell interactions.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) treated with belimumab
- Participants
- 19 patients
- Comparison
- Immunophenotypic changes before and 3 months after belimumab, and their association with treatment response at 6 months
- Outcome
- Association of early B cell changes (PC1, PC2) with treatment response
- Follow-up
- 6 months
Main finding
As reported in the abstract
Therapeutic response at 6 months by lower PC2 (increased BAFF receptor (BAFF-R) expression, decreased % naïve B cells)
Lower PC2 associated with subsequent therapeutic response, OR
5.3
95% CI 1.2–24p = .031
Further findings
Baseline effector memory CD3+CD4+ T cells
- Higher % at baseline associated with lower PC2 and therapeutic response
PC1 increase (increased B-cell maturation antigen (BCMA) and TACI expression, increased % class-switched memory B cells)
- Associated with both T and B cell activation
Original publication
Association between early immunophenotypic changes and therapeutic response of belimumab in patients with systemic lupus erythematosus. Lupus. Published 31 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →